ImageneBio (IMA) Operating Income (2020 - 2025)
ImageneBio (IMA) posted Operating Income of -$26.6 million for Q3 2025, down 203.93% sequentially from -$8.8 million in Q2 2025, and down 1206.19% YoY from $2.4 million in Q3 2024.
ImageneBio (IMA) Operating Income (2020 - 2025) Analysis & Trends
ImageneBio has reported Operating Income for 6 years, with the latest figure at -$26.6 million in Q3 2025.
- Quarterly Operating Income fell 1206.19% year-over-year to -$26.6 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was -$69.5 million (down 19.76% YoY) and the FY2024 annual result came in at -$59.0 million, up 21.8% from the prior year.
- Operating Income fell to -$26.6 million in Q3 2025 per IMA's latest filing, from -$8.8 million in the prior quarter.
- Over five years, Operating Income peaked at $2.8 million in Q4 2021 and troughed at -$28.1 million in Q4 2024.
- A 5-year average of -$15.1 million and a median of -$15.8 million in 2024 frame the typical range for Operating Income.
- The sharpest annual moves came in 2021 and 2025: Operating Income jumped 110.72% in 2021, then slumped 1206.19% in 2025.
- Over 5 years, Operating Income stood at $2.8 million in 2021, then tumbled by 641.33% to -$15.1 million in 2022, then sank by 44.95% to -$21.9 million in 2023, then fell by 28.33% to -$28.1 million in 2024, then rose by 5.41% to -$26.6 million in 2025.
- According to Business Quant data, Operating Income over the past three periods registered -$26.6 million, -$8.8 million, and -$6.0 million for Q3 2025, Q2 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 231.44 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.55 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 133.12 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -375.75 Mn |
| 10 | ImageneBio | 48.60 Mn | -86.75 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -26.59 Mn |
| Jun 30, 2025 | -8.75 Mn |
| Mar 31, 2025 | -6.00 Mn |
| Dec 31, 2024 | -28.12 Mn |
| Sep 30, 2024 | -2.04 Mn |
| Jun 30, 2024 | -15.82 Mn |
| Mar 31, 2024 | -18.23 Mn |
| Dec 31, 2023 | -21.91 Mn |
| Sep 30, 2023 | -19.50 Mn |
| Jun 30, 2023 | -18.49 Mn |
| Mar 31, 2023 | -15.52 Mn |
| Dec 31, 2022 | -15.11 Mn |
| Sep 30, 2022 | -17.88 Mn |
| Jun 30, 2022 | -20.95 Mn |
| Mar 31, 2022 | -16.96 Mn |
| Dec 31, 2021 | 2.79 Mn |
| Sep 30, 2021 | -14.52 Mn |
| Jun 30, 2021 | -12.69 Mn |
| Mar 31, 2021 | -9.72 Mn |
| Dec 31, 2020 | -26.05 Mn |